Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SA4503 for major depressive disorder
2007-002740-16Phase 2Completed
- Sponsor
- M's Science Corporation
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cutamesine in major depressive disorder (MDD) (3 arms), sponsored by M's Science Corporation. Primary endpoint: Change in MADRS score from baseline to Week 8. Started Jun 2007; status: completed.
02
Drugs
cutamesine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-002740-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002740-16.